l e t t e r s UK Biobank is among the world's largest repositories for phenotypic and genotypic information in individuals of European ancestry 1 . We performed a genome-wide association study in UK Biobank testing ~9 million DNA sequence variants for association with coronary artery disease (4,831 cases and 115,455 controls) and carried out meta-analysis with previously published results. We identified 15 new loci, bringing the total number of loci associated with coronary artery disease to 95 at the time of analysis. Phenome-wide association scanning showed that CCDC92 likely affects coronary artery disease through insulin resistance pathways, whereas experimental analysis suggests that ARHGEF26 influences the transendothelial migration of leukocytes.
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Coronary artery disease (CAD) is a leading cause of disability and mortality worldwide 2 . Genome-wide association studies (GWAS) have provided new clues to the pathophysiology for this common, complex disease. Largely using a case-control design with cases ascertained on the basis of CAD status, published studies have highlighted at least 80 loci reaching genome-wide significance [3] [4] [5] [6] [7] [8] [9] .
Population-based biobanks such as UK Biobank offer new potential for genetic analysis of common, complex diseases. New opportunities include increased scale, a diverse range of traits, and the ability to explore a fuller spectrum of phenotypic consequences for identified DNA variants. Leveraging the UK Biobank resource, we sought to (i) perform a genetic discovery analysis; (ii) explore the phenotypic consequences and tissue-specific effects associated with CAD risk alleles; and (iii) characterize the functional consequences of a riskassociated mutation in a promising pathway.
We designed a three-stage GWAS (Fig. 1) .
In stage 1, we tested the association of DNA sequence variants with CAD in UK Biobank. In stage 2, we took forward 2,190 variants that reached nominal significance in stage 1 (P < 0.05) for meta-analysis with results from an exome-focused array analysis in 42,355 cases and 78,240 controls 6 . In stage 3, we took forward 387,174 variants that reached nominal significance in stage 1 and were not tested in stage 2 for meta-analysis with results from a genome-wide imputation study in 60,801 cases and 123,504 controls 5 . For each variant, we combined statistical evidence across stages 1 and 2 (or stages 1 and 3) and set a statistical threshold of P < 5 × 10 −8 for genome-wide significance.
The characteristics of UK Biobank participants stratified by presence of CAD are presented in Supplementary Table 1 . CAD cases were more likely to be older, male, on lipid-lowering therapy, to have a history of smoking, and to be affected with type 2 diabetes. After quality control, 9,061,845 DNA sequence variants were tested for association in 4,831 patients with CAD and 115,455 controls in UK Biobank (stage 1). A total of 269 variants at five distinct loci met the genome-wide significance threshold (P < 5 × 10 −8 ) ( Supplementary  Figs. 1 and 2) . All five loci have previously been reported 5, [10] [11] [12] [13] . In UK Biobank, the 9p21-CDKN2B-AS1 variant rs4977575 (NC_000009.12: g.22124745C>G) was the top association result (49% frequency for the G allele; odds ratio (OR) = 1.24, 95% confidence interval (CI) = 1.19-1.29; P = 5.40 × 10 −23 ); the other four loci were 1p13-SORT1, PHACTR1, LPA, and KCNE2 (Supplementary Table 2 ). For a set of previously reported CAD-associated loci 5 , we compared effect estimates from the published literature with those from the current analysis in UK Biobank and found strong positive correlation in effect sizes (β = 0.92, 95% CI = 0.77-1.06; P = 1.8 × 10 −17 ; Supplementary  Fig. 3) ; these results validate our CAD phenotype definition in UK Biobank. A total of 513,403 variants exceeded nominal significance (P < 0.05) and were taken forward to stage 2 or 3.
After meta-analysis, 15 new loci exceeded genome-wide significance (Tables 1 and 2), bringing the total number of established CAD loci to 95 at the time of this analysis. Of note, while this manuscript l e t t e r s was under review, one of the 15 loci (HNF1A) was reported 9 . Effect allele frequencies for the 15 newly identified loci ranged from 13% to 86%, with effect sizes ranging from 1.05 to 1.08. Descriptions of relevant loci appear in Supplementary Table 3, and regional association plots for new CAD loci are shown in Supplementary Figures 4-6 .
To move from these 15 DNA sequence variants to biological insights, we took two approaches: phenome-wide association scanning and functional analysis. Understanding the full spectrum of phenotypic consequences of a given DNA sequence variant may shed light on the mechanism by which a variant or gene leads to disease. Termed a 'phenome-wide association study' , or PheWAS, this approach tests the association of a mapped disease-associated variant with a broad range of human phenotypes 14 . In collaboration with Genomics plc, we conducted a PheWAS combining UK Biobank data, mRNA transcript phenotypes in the Genotype-Tissue Expression (GTEx) Project data set 15 , and an integrated set of GWAS results from a variety of publically available sources [16] [17] [18] [19] [20] [21] [22] [23] [24] .
We found that several of the newly identified DNA sequence variants correlated with a range of human traits ( Fig. 2 and Supplementary Tables 4 and 5). For example, the intronic variant rs10841443 within RP11-664H17.1 is in close proximity to PDE3A, which encodes a phosphodiesterase previously implicated in an autosomal dominant form of hypertension 25 . PheWAS showed an association for this variant with diastolic blood pressure 26 , suggesting that this locus may be acting through hypertension. The variant rs2244608 within HNF1A has previously been associated with LDL cholesterol, elevated levels of which represent a causal path to atherosclerosis 16 . The variant rs7500448 within CDH13 (encoding cadherin 13 or T-cadherin), a vascular adiponectin receptor implicated in hypertensive and insulin resistance biology 27 , associates with plasma adiponectin levels. Variant rs2972146 is downstream of IRS1 (encoding insulin receptor substrate-1; ref. 24 ) and is a cis expression quantitative trait locus (eQTL) for IRS1 expression in adipose tissue. rs2972146 associates with a range of phenotypes seen in the setting of insulin resistance, including HDL cholesterol, triglycerides, adiponectin, fasting insulin, and type 2 diabetes.
Additional compelling insights from the PheWAS emerged at the CCDC92 locus. Across 25 distinct traits and disorders, we observed significant association (P < 0.00013) for CCDC92 p.Ser70Cys (rs11057401) with body fat percentage and waist-to-hip circumference ratio, as well as plasma HDL, triglyceride, and adiponectin levels. The directionalities of these associations are hallmarks of insulin resistance and lipodystrophy 17, 28 , and the association with plasma adiponectin levels localizes these genetic effects to adipose tissue. Recent work has highlighted two candidate genes at this locus, CCDC92 and DNAH10 (ref. 29) , and further experimental work is necessary to define the causal gene.
However, a few of the CAD-associated loci (FN1, LOX, ITGB5, and ARHGEF26) did not significantly associate with any of the studied risk factor traits and, thus, appear to function through pathways beyond known CAD risk factors ( Fig. 2 and Supplementary Tables 3-5). A common variant within an intron of FN1 (ref. 30 ; encoding fibronectin 1) and a missense variant in LOX 31 (encoding lysyl oxidase) suggest potential links to extracellular matrix biology. Of note, rare coding mutations in LOX were recently described to cause Mendelian forms of thoracic aortic aneurysm and dissection 32, 33 , highlighting a potential common link between atherosclerosis and aortic disease, possibly involving altered extracellular matrix biology. A variant downstream of ITGB5 (ref. 34 ; encoding integrin subunit β5) suggests a role for pathways underlying cell adhesion and migration.
In aggregate, our analysis brings the total number of known CADassociated loci to 95 (refs. [3] [4] [5] [6] [7] [8] [9] , and in Figure 3 we organize these loci into plausible pathways. Of note, the causal variant, gene, cell type, or mechanism has been definitively identified for only a few of these loci and, as such, additional experimental research will be required, particularly at the >50% of loci without an apparent link to known risk factors.
For one of the new loci not related to known risk factors, ARHGEF26 (encoding Rho guanine nucleotide exchange factor 26), we performed functional studies. Prior experimental work had connected this gene with atherosclerosis in mice 35 . Earlier studies also established a role for ARHGEF26 in facilitating the transendothelial migration of leukocytes, a key step in the initiation of atherosclerosis 36, 37 . Genes for variants that are outside the transcript boundary of the protein-coding gene are shown in parentheses. Chr., chromosome; CI, confidence interval; EA, effect allele; EAF, effect allele frequency; OR, odds ratio.
l e t t e r s
How could the ARHGEF26 mutation encoding Leu29 lead to a gain-of-function phenotype? We evaluated the functional impact of this mutation in two ways, addressing ARHGEF26 activity and quantity. First, we assessed whether the mutation introducing Leu29 could alter ARHGEF26 nucleotide-exchange activity on RhoG. To this end, we developed a GTP-GDP nucleotide-exchange assay using recombinant full-length human ARHGEF26 (wild type or Leu29) and Figure 2 Phenome-wide association results for 15 loci new at the time of analysis. For the 15 new CAD risk variants identified in our study, z scores (aligned to the CAD risk allele) were obtained from the Genomics plc Platform and UK Biobank. A positive z score (red) indicates a positive association between the CAD risk allele and the disease or trait, whereas a negative z score (blue) indicates an inverse association. Boxes are outlined in green if the variant is significantly (P < 0.00013) associated with the given trait. Adj, adjusted; BMI, body mass index; BP, blood pressure; crea, creatinine; cys, cystatin-c; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate.
ARHGEF26 has been shown to activate RhoG GTPase by promoting the exchange of GDP for GTP and contributing to the formation of ICAM1-induced endothelial docking structures that facilitate leukocyte transendothelial migration 36, 37 . In addition, Arhgef26-null mice, when crossed with atherosclerosis-prone Apoe-null mice, displayed less aortic atherosclerosis 35 .
At ARHGEF26 p.Val29Leu (rs12493885), the allele encoding Leu29, observed in 85% of participants, was associated with increased risk for CAD. We first examined the hypothesis that a haplotype block containing this allele might alter expression of ARHGEF26 in coronary artery. Although this genomic region demonstrates eQTL effects in a variety of tissues, there was no evidence of alteration of ARHGEF26 expression in coronary artery from either eQTL or allele-specific expression analysis (Supplementary Fig. 7) . To further evaluate the possibility that a haplotype containing the allele for Leu29 might alter gene expression, we performed luciferase reporter assays. We cloned a 2.5-kb region immediately upstream of the ARHGEF26 start codon consisting of the promoter, 5′ UTR, and regions with Encyclopedia of DNA Elements (ENCODE) annotations suggestive of potential cisacting elements. We obtained the reference (in linkage disequilibrium (LD) with the Val29-encoding G allele) and alternative (in LD with the Leu29-encoding C allele) haplotypes of this region from human cells heterozygous at rs12493885. We then coupled each haplotype with a luciferase reporter and measured luciferase activity ( Supplementary  Fig. 8 ). In HEK293 cells, human aortic endothelial cells (HAECs), and human umbilical vein endothelial cells (HUVECs), there was not a significant difference in luciferase activity between the reference and alternative haplotypes. These data suggest that the ARHGEF26 allele encoding Leu29 may confer CAD risk via mechanisms other than an effect on ARHGEF26 transcription or promoter activity in disease-relevant tissue.
Next, we examined the hypothesis that ARHGEF26 p.Val29Leu might influence disease risk by altering the encoded protein. We knocked down endogenous ARHGEF26 through small interfering RNA (siRNA) and observed decreased leukocyte transendothelial migration, leukocyte adhesion on endothelial cells, and vascular smooth muscle cell proliferation 38 ( Fig. 4 and Supplementary Fig. 9 ). Overexpression of exogenous wild-type ARHGEF26 rescued these phenotypes. However, overexpression of the exogenous ARHGEF26 Leu29 mutant led to rescued phenotypes that consistently exceeded those observed with overexpression of wild-type protein. These data support the hypothesis that the ARHGEF26 allele encoding Leu29 associated with increased CAD risk may lead to a gain of protein function. l e t t e r s human RhoG 39 . In a cell-free system, equal amounts of wild-type and Leu29 ARHGEF26 protein were incubated with RhoG preloaded with GDP. After 60 min, we observed no significant difference in nucleotide-exchange activity between the wild-type and mutant ARHGEF26 proteins ( Supplementary Fig. 10 ). Second, we assessed whether the allele encoding Leu29 affects the cellular abundance of ARHGEF26 protein. We examined this possibility by treating cells expressing wild-type or Leu29 mutant ARHGEF26 with cycloheximide, a protein synthesis inhibitor, and compared ARHGEF26 degradation over time by immunoblotting. In comparison to wild-type ARHGEF26, the Leu29 mutant displayed a longer half-life ( Supplementary Fig. 11) . While further work is needed to understand the mechanism in vivo, our in vitro results suggest that the gain-of-function phenotype observed may be secondary to resistance of the Leu29 mutant protein to degradation.
Our study should be interpreted within the context of its limitations. First, we focused on participants of European ancestry within UK Biobank, and results may therefore not be generalizable to other populations. Second, our CAD phenotype definitions are based largely on interviews and electronic health records, and this may result in misallocation of case status. However, such misclassification should reduce statistical power for discovery and bias results toward the null. Finally, although we observed no evidence of robust changes in ARHGEF26 expression associated with the haplotype encoding Leu29 in disease-relevant tissue, it is possible that other regulatory mechanisms may potentiate the gain-of-function phenotypes we observed.
In summary, we performed a gene discovery study for CAD using a large population-based biobank, identified 15 new loci, and explored the phenotypic consequences of CAD risk variants through PheWAS and in vitro functional analysis. These findings permit several conclusions. First, CAD cases phenotyped via electronic health records and verbal interviews exhibit similar genetic architectures to those derived in epidemiological cohorts and can prove useful in gene discovery efforts. Second, PheWAS with risk variants can provide initial clues to how DNA sequence variants may lead to disease. Lastly, considerable experimental evidence in cells and rodents has suggested that transendothelial migration of leukocytes is a key step in the formation of atherosclerosis 40 ; here we provide genetic support in humans for a role of this pathway in CAD. All other individuals were defined as controls. In total, genotypes were available for 120,286 participants of European ancestry.
URLs
In stage 2, we took forward 2,190 variants that reached nominal significance in stage 1 for meta-analysis in the CARDIoGRAM Exome Consortia exome array analysis that incorporated 42,355 cases and 78,240 controls 6 (Supplementary Table 6 ). In stage 3, we took forward 387,174 variants that reached nominal significance in stage 1 (and were not available in stage 2) for meta-analysis in the CARDIoGRAMplusC4D 1000 Genomes-imputed study containing 60,801 cases and 123,504 controls 5 . Informed consent was obtained for all participants, and UK Biobank received ethical approval from the Research Ethics Committee (reference number 11/NW/0382). Our study was approved by a local institutional review board at Partners Healthcare (protocol 2013P001840).
Genotyping and quality control. UK Biobank samples were genotyped using either the UK BiLEVE 42 or UK Biobank Axiom array, with array analysis performed in 33 separate batches of samples by Affymetrix. A total of 806,466 directly genotyped DNA sequence variants were available after variant quality control. The UK Biobank team then performed imputation from a combined 1000 Genomes and UK10K reference panel; phasing was performed using SHAPEIT3 and imputation was carried out via IMPUTE3. The variant-level quality control exclusion metrics applied to imputed data for GWAS included the following: call rate < 95%, Hardy-Weinberg equilibrium P <1 × 10 −6 , posterior call probability < 0.9, imputation quality < 0.4, and MAF < 0.005. Sex chromosome and mitochondrial genetic data were excluded from this analysis. In total, 9,061,845 imputed DNA sequence variants were included in our analysis. For sample quality control, the UK Biobank analysis team removed individuals with relatedness corresponding to third-degree relatives or closer, and an additional 480 samples with an excess of missing genotype calls or more heterozygosity than expected were excluded. In total, genotypes were available for 120,286 participants of European ancestry.
Statistical analysis. Stage 1 association analysis.
BOLT-LMM software 43 was used to generate linear mixed models (LMMs) for association testing. CAD case status was analyzed while adjusting for age, sex, and chip array at runtime. This analysis was used to derive statistical significance. As effect estimates from BOLT-LMM software are unreliable because of the treatment of binaryphenotype data as quantitative data, we performed logistic regression to derive effect estimates for each variant that exceeded genome-wide significance. Effect estimates for top variants were derived from logistic regression using allelic dosages adjusting for age, sex, chip at runtime, and ten principal components under the assumption of additive effects using the R v3.2.0 and SNPTEST statistical software programs. Stage 2 and 3 meta-analysis. In stage 2, top variants (P < 0.05) from UK Biobank were then meta-analyzed with exome chip data from the CARDIoGRAM Exome Consortia 6 . Tested variants in the CARDIoGRAM exome array study were analyzed through logistic regression with an additive model adjusting for study-specific covariates and principal components of ancestry as appropriate. Top variants from UK Biobank that were not available for analysis in the CARDIoGRAM exome array study were then meta-analyzed with data from the 1000 Genomes-imputed CARDIoGRAMplusC4D GWAS 5 in stage 3.
Given differences in effect size units between the UK Biobank stage 1 data and the CARDIoGRAM exome or 1000 Genomes-imputed CARDIoGRAMplusC4D data, both stage 2 and stage 3 meta-analyses were performed via a weighted z-score method, adjusting for an unbalanced ratio of cases to controls. To derive effect size estimates for variants exceeding genomewide significance, we meta-analyzed logistic regression results using inversevariance weighting with fixed effects (METAL software) 44 . We set a combined statistical threshold of P < 5 × 10 −8 for genome-wide significance. P values reported in analysis stages 1-3 are all two-sided.
Phenome-wide association study. For all 15 new DNA sequence variants associated with CAD in our study, we collaborated with Genomics plc to conduct a PheWAS. This PheWAS used Genomics plc Platform, UK Biobank, and GTEx Consortium eQTL data. The Genomics plc Platform includes PheWAS data across 545 distinct molecular and disease phenotypes, at an integrated set of over 14 million common variants, from 677 GWAS. UK Biobank analyses within the Genomics plc Platform were conducted under a separate research agreement. We selected 25 phenotypes across a range of relevant diseases and metabolic and anthropometric traits from either previously published GWAS data sets or UK Biobank. Complete details of phenotype definitions, sample sizes, and GWAS data sources are provided in Supplementary Tables 7 and 8 .
In the PheWAS, quantitative traits were standardized to have unit variance, imputation was performed to generate results for all variants within the 1000 Genomes reference panel, and P values were recalculated based on a Wald test statistic for uniformity.
Phenotypes were declared to be significantly associated with a risk variant if they achieved a Bonferroni-corrected P value of <0.00013 (0.05/(25 traits × 15 DNA sequence variants)). Phenome scan results were then depicted in a heat map based on the z scores for all variant-disease/trait associations aligned to the CAD risk allele as implemented in the gplots package in R v3.2.0. To identify loci that might influence gene expression, we used previously published cis-eQTL mapping data from the Genotype-Tissue Expression (GTEx) Project across 44 tissues 15 . We queried the 15 new variants identified in our study for overlap with genome-wide significant variant-gene pairs from the GTEx portal.
Allele-specific expression analysis. Allele-specific expression (ASE) data from the GTEx Project were obtained from dbGaP (accession phs000424.v6.p1). The generation of these data is summarized in ref. 15 and relied on methods described earlier 45 . In brief, only uniquely mapping reads with base quality ≥10 at a SNP were counted, and only SNPs covered by at least eight reads are reported. For ARHGEF26 p.Val29Leu, ASE counts were available for 20 heterozygous individuals. A two-sided binomial test was used to identify SNPs with significant allelic imbalance in each individual, and Benjamini-Hochberg-adjusted P values were calculated across all sites measured in an individual.
Luciferase reporter assays. HUVECs heterozygous at rs12493885 from European-ancestry donors were identified by SNP genotyping. A 2.9-kb genomic fragment spanning the region from upstream of ARHGEF26 to exon 2 (rs12493885) was cloned into the pMiniT 2.0 vector (New England BioLabs) using genomic DNA from heterozygous HUVECs as a template and sequenced for the reference and alternative alleles. The reference and alternative haplotypes located from −2,516 to +2 with respect to ARHGEF26 (NC_000003. 12:154,119,477-154,121,994) were amplified from the 2.9-kb region by PCR with primers designed to create 5′ NheI and 3′ HindIII restriction sites in the PCR products. The amplified fragments were subcloned between the NheI and HindIII sites of the promoterless firefly luciferase (luc2) expression vector pGL4.10 (Promega) to create two plasmids: pGL4.10-Ref and pGL4.10-Alt. Promoterless pGL4.10-control and pGL4.73[hRluc/SV40] vector containing the Renilla luciferase hRluc reporter gene and an SV40 early enhancer/promoter were used as the negative control and co-reporter, respectively. HEK293 cells, HAECs, and HUVECs were cotransfected with equal amounts of luc2 expression plasmid (pGL4.10-control, pGL4.10-Ref, and pGL4.10-Alt) and pGL4.73 vector by Lipofectamine 2000. Cells were collected at 48 h after transfection followed by a Dual-Glo Luciferase Assay (Promega) to measure firefly and Renilla luciferase activities. Firefly luciferase activity was normalized to Renilla luciferase activity in the same sample and is expressed as the fold change relative to the pGL4.10-control group.
Nucleotide-exchange assays. Full-length human ARHGEF26 (wild type or Leu29) and human RhoG (residues 1-188) proteins, both with N-terminal His-SUMO tags, were expressed in Escherichia coli BL21 (DE3) cells in TB medium. Nucleotide-exchange assay samples were prepared in buffer containing 10 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl 2 , 0.5 µM MANT-GTP, and 2 mM TCEP with 1 µM ARHGEF26. Just before reading, RhoG protein, preloaded with GDP, was added to a final concentration of 0.4 µM. MANT-GTP fluorescence was monitored for 60 min on a SpectraMax M2 at 37 °C using an excitation wavelength of 280 nm and an emission wavelength of 440 nm with a cutoff of 435 nm. Fluorescence data were imported into Prism GraphPad for analysis.
Functional characterization of ARHGEF26 p.Val29Leu in arterial tissue.
To investigate the functional effects of ARHGEF26 p.Val29Leu (rs12493885), we knocked down the expression of endogenous ARHGEF26 in cultured HAECs and HCASMCs by RNA interference. We then overexpressed wildtype or mutant (Leu29) ARHGEF26 resistant to siRNA and measured leukocyte transendothelial migration, leukocyte adhesion on endothelial cells, and HCASMC proliferation in vitro. We also evaluated the degradation of wild-type and Leu29 ARHGEF26 with a cycloheximide chase assay and immunoblotting. Additional details on experimental techniques are provided in the Supplementary Note.
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Data exclusions
Describe any data exclusions. Non-European ancestry individuals, or those who did not pass quality control
Replication
Describe whether the experimental findings were reliably reproduced. Replication was performed using data from one of 2 sources: 1) CARDIoGRAM exome consortium CAD summary statistics, or 2) CARDIoGRAMplusC4D imputed CAD summary statistics
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
N/A, no randomization performed for GWAS analysis
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was performed for our GWAS analysis
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
